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Abstract
Introduction: Trichotillomania, classified as an impulse control disorder in the Diagnostic and Statistical Manual of
Mental Disorders, is characterized by the recurrent pulling out of one’s hair, resulting in noticeable hair loss. The
condition has a varied etiology. Specific serotonin reuptake inhibitors are considered the treatment of choice;
however some patients fail to respond to this class of drugs. A few older reports suggest possible benefit from
treatment with bupropion.
Case presentation: A 23-year-old Asian woman with fluoxetine non- responsive trichotillomania was treated with
sustained release bupropion (up to 450 mg/day) and cognitive behavior therapy. She demonstrated clinically
significant improvement on the Clinical Global Impression - Improvement scale by week 13. The improvement
persisted throughout the 12-month follow-up period.
Conclusions: The present case report may be of interest to psychiatrists and dermatologists. Apart from the
serotonergic pathway, others, such as the mesolimbic pathway, also appear to be involved in the causation of
trichotillomania. Bupropion may be considered as an alternative pharmacological treatment for patients who do
not respond to specific serotonin reuptake inhibitors. However, this initial finding needs to be confirmed by well
designed double-blind placebo controlled trials.
Introduction
Trichotillomania (TTM) is characterized by a compul-
sive urge to pull out one’s own hair, leading to notice-
able hair loss, distress, and social or functional
impairment. TTM is usually confined to one or two
sites, mainly the scalp, eyebrows, and eyelashes, but can
also involve other parts of the body.
TTM is classified as an impulse control disorder in
the Diagnostic and Statistical Manual of Mental Disor-
ders, fourth edition (DSM-IV), and is believed to be
related to obsessive-compulsive spectrum disorders
[1,2]. Patients with obsessive-compulsive disorder
(OCD) and patients with TTM share overlapping
comorbidity, familial transmission, treatment response,
and difficulties in suppressing inappropriate repetitive
behaviors, indicating that there is an underlying dysre-
gulation in inhibitory control processes [3].
OCD has a fluctuating course with exacerbations and
remissions, and the symptoms change over time in
terms of focus (for example, ritualistic washing, check-
i n gs t o v e s ,a n ds oo n ) .U n l i k eO C D ,T T Mh a sb o t h
impulsive as well as compulsive elements. It does not
occur in response to obsessive thoughts, but rather
because of an irresistible urge to pull hair at leisure and
the sense of satisfaction when the hair is pulled. Addi-
tionally, patients with TTM usually present only with
hair pulling without evolution to other compulsive
rituals, and usually do not have a fluctuating course.
Depression and anxiety is less in TTM compared with
OCD. Long-term response to treatment with specific
serotonin reuptake inhibitors (SSRIs) is consistent in
OCD while it is variable in TTM [4-6].
Genetic, classificatory and pharmacological treatment
s t u d i e sh a v es u g g e s t e dt h ep o s s i b i l i t yo fa d d i c t i v eb e h a -
vior in TTM [4]. As in other addictive disorders (such
as pathological gambling), bupropion may be considered
in the management of TTM, as there is emerging evi-
d e n c ef o rt h er o l eo fd o p a m i n ep a t h w a y si nt h i sc o n d i -
tion [3].
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Our patient was a 23-year-old unmarried, unemployed
woman graduate from a middle socioeconomic status
and urban Asian background. She had a six-year history
of patchy hair loss from her scalp. She had earlier con-
sulted a dermatologist who referred her to a psychiatrist.
She walked into our consultation room with her head
covered with a scarf. She had a short haircut and there
were many bald patches, 5 cm to 10 cm in area, on her
scalp. The hair, particularly in the parietal region of
both sides of the head, was very thin, brittle and uneven.
Our patient had an uncontrollable, irresistible, repeti-
tive urge to pull out her scalp hair. The hair-pulling
behavior had first appeared when she was 17 years of
age, had completed school and was entering college.
There was no evidence of any significant stressors in
her life. The hair pulling had become particularly dis-
tressing and problematic over the past six months and
she described her present condition as ‘tremendously
out of control’. There was a significant deterioration in
her academic performance and social functioning.
The hair pulling spells occurred on a daily basis, just
before bedtime, when she was alone in her room listen-
ing to the radio, or watching television. The hair pulling
used to be more severe when she was stressed. She
reported a feeling of mounting tension before the act of
hair pulling, with an accompanied sensation of itching.
The tension was alleviated when she pulled the hair out.
Pulling of hair involved twisting each hair around a fin-
ger, mostly from the sides of her head near her ears.
She reported a sense of satisfaction in hearing the sound
of the hair being pulled out, accompanied by pleasurable
sensations. She would pull out countless hairs over few
hours, resulting in a bald patch on the scalp. After the
hair was pulled, she would examine the root of the hair.
Later, she would secretly dispose of the plucked out hair
after neatly packing them in a cover.
She felt guilty and embarrassed by her hair-pulling
behavior and often wore her hair tied back. She was
more self-conscious about the bald patches behind the
ears. She used scarves to camouflage her disfigured
scalp while going out. She had good insight into her ill-
ness, and recognized that her mental state was contri-
buting to her symptoms.
Our patient was pre-morbidly well adjusted with no
significant medical or family history. There was also no
history of substance use or suicide attempts. She was
diagnosed to have TTM (impulse control disorder not
otherwise specified) as per DSM-IV criteria [1]. There
was no comorbid Axis I psychiatric disorders, including
mood disorder. OCD was ruled out in our patient as the
hair pulling (i) used to occur in leisure time only, (ii)
was not in response to obsessive thoughts, but rather
because of irresistible urges, (iii) was followed by a sense
of satisfaction, (iv) was not associated with any other
OCD symptoms, and (v) was not associated with
depression.
At various time points, different instruments were
applied to measure her treat m e n tr e s p o n s e( T a b l e1 ) .
TTM behavior was measured with The Massachusetts
General Hospital Hair Pulling Scale (MGHHPS) and
National Institute of Mental Health Trichotillomania
Symptom Severity and Impairment Scale (NIMH-TSS
and NIMH-TIS) [5,6]. MGHHPS is a self-report mea-
sure of the severity of hair pulling urges and behavior,
efforts to resist urges, control over the problem, and
associated distress [5]. Higher scores reflect greater
severity. The NIMH-TSS and NIMH-TIS are clinician
rating scales [6]. The NIMH-TSS is a five-item measure
assessing average hair-pulling episode duration during
the past week and on the previous day, thoughts preced-
ing the pulling episode, resistance to urges, distress, and
interference. The NIMH-TIS is an 11-point scale asses-
sing overall impairment in a patient’s life due to TTM.
Clinical Global Impression - Severity and Improvement
scales (CGI-S and CGI- I) are clinician-rated instru-
ments to assess the baseline severity and improvement
in a psychiatric disorder [7]. Presence of depression was
assessed with the Hospital Anxiety Depression Rating
Scale - Depression subscale (HADS-D) [8].
Our patient was initially started on fluoxetine 20 mg/
day (gradually increasing the dose up to 80 mg/day by
week eight), clonazepam 0.5 mg/day (tapered off by
week three) and continuous cognitive behavior therapy
(CBT). By week eight, despite the reasonably adequate
dose and treatment duration, there was minimal
improvement in hair-pulling behavior. Hence, at week
eight, bupropion sustained release (bupropion-SR) was
initiated at 150 mg/day, and increased to 300 mg/day at
week 10. Fluoxetine was tapered off by week 11. By
week 12, there was a mild improvement in our patient’s
hair pulling behavior, and the dose of bupropion-SR was
increased to 450 mg/day, in divided doses. At this dose,
at week 13, our patient experienced significant clinical
improvement in TTM. She continued to show sustained
improvement during the 6 and 12-month follow-ups
(Figure 1). CBT was started at the beginning of treat-
ment, and was continued throughout the one-year fol-
low-up period. Bupropion-SR was well tolerated, except
for few mild adverse effects such as nausea and nervous-
ness during the initial two weeks, which resolved with-
out any intervention.
Discussion
Our patient was initially treated with fluoxetine, a speci-
fic serotonin reuptake inhibitor (SSRI), up to 80 mg/day
for adequate duration along with CBT, but there was
minimal improvement. Very few case reports are
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Scales/score
range
Week 0 Week 8 Week 12 Week 13 Week 24 (6
months)
Week 48 (12
months)
CGI-S (1-7) 4, moderate symptoms 4, moderate
symptoms
4, moderate
symptoms
2, borderline
mentally ill
2, borderline
mentally ill
2, borderline
mentally ill
CGI-I (1-7) NA 4, no change 3, mild
improvement
2, much
improvement
2, much
improvement
1, very much
improved
MGHHPS (0-28) 21, moderate symptoms 20, moderate
symptoms
18, moderate
symptoms
10, mild symptoms 9, mild
symptoms
9, mild symptoms
NIMH-TSS (0-30) 23, moderate symptoms 22, moderate
symptoms
19, moderate
symptoms
12, mild symptoms 10, mild
symptoms
8, mild
symptoms
NIMH-TIS (0-10) 8, moderate-severe
impairment
8, moderate-
severe
impairment
7, moderate-severe
impairment
3, minimal
impairment
2, minimal
impairment
1, minimal
impairment
HADS-D (0-21) 5, normal: no depression - - - - 3, normal: no
depression
CGI-S/I = Clinical Global Impression - Severity/Improvement; HADS-D = Hospital Anxiety Depression Rating Scale - Depression; MGHHPS = Massachusetts General
Hospital Hair Pulling Scale; NIMH-TIS/TSS = National Institute of Mental Health Trichotillomania Impairment Scale/Trichotillomania Symptom Severity Scale.
(week 0) Fluoxetine 20 mg/day, Clonazepam 0.5 mg/day, CBT*  
Clonazepam tapered-off over 3 weeks  
(week 8) Fluoxetine 80 mg/day, CBT*                   minimal improvement
**
(Started on Bupropion-SR 150 mg/day)  
Fluoxetine tapered-off over 3 weeks (by week 11)  
(week 10)                                         Bupropion-SR increased to 300 mg/day,
          C B T *
(week 12)                        mild improvement
**
Bupropion-SR increased to 450 mg/day, CBT*  
               (week 13)                         much improvement
**
(week 24, 6 months)                               much improvement
**
(week 48, 12 months)         very much improved
**
Bupropion-SR 450 mg/day and CBT* continued 
Figure 1 Flowchart depicting the sequence of events in our patient’s case. *CBT = Cognitive Behavior Therapy **Improvement based on
Clinical Global Impression - Improvement (CGI-I) scale scores
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bupropion in the treatment of TTM. In our patient,
bupropion-SR was given up to 450 mg/day, the dosage
used in other studies [3,9,10]. Bupropion-SR was well
tolerated and was beneficial in reducing the hair-pulling
behavior. The observed improvement does not appear
to be related to the anti-depressant effect of bupropion,
since the HADS-D score was within normal limits at
baseline and did not change significantly at the end of
the one-year follow-up. Also, clinically, there was no evi-
dence of depression throughout the follow-up period.
Similar findings were reported by Dannon et al. [3].
TTM is proposed to be a heterogeneous disorder that
overlaps with OCD, impulse control disorders and also
addictive disorders. There is an association of TTM
with attention deficit hyperactivity disorder and impul-
sive behavior [3].
Traditionally, serotonin has been the principal neuro-
transmitter implicated in TTM and other impulse con-
trol disorders. However, recent literature strongly
supports the role of dopamine in the pathophysiology of
TTM [10]. Lochner et al. have theorized that TTM is
more impulsive than compulsive in nature [4]. TTM is
not just an impulsive-compulsive disorder, but also
appears to have an addictive component to it. Dannon
et al. proposed that TTM (like addictive disorders) is
characterized by compulsive seeking, and consequently
obtaining the substance of choice (that is, hair), with
progressive loss of behavior control [3]. Thus, like
pathological gambling, TTM appears to be more like an
addictive disorder, where the mesolimbic dopamine
reward pathway and prefrontal cortex are implicated.
Thus, TTM may be conceptualized as an impulsive-
compulsive-addictive spectrum disorder. It has been
hypothesized that specific subtypes of TTM exist with
specific patterns of treatment response [3,9]. Many
pharmacological agents have been reported to be useful
in TTM. These include SSRIs, anti-convulsants, anti-
psychotics and naltrexone. Earlier studies, however, have
failed to show efficacy of SSRI treatment [3].
Bupropion is useful in nicotine, caffeine, alcohol and
other addictive disorders through its action on the
mesolimbic pathways, where it inhibits the reuptake of
dopamine and norepinephrine. There is now also evi-
dence that bupropion similarly helps in TTM (and also
pathological gambling) by diminishing the heightened
arousal and pleasurable relief [10,11]. Hence, bupropion
may be considered as an effective alternative in patients
with TTM not responding to SSRIs.
There is definite evidencet h a tC B Ti sb e n e f i c i a li n
TTM, and the synergistic benefit of CBT in our
patient cannot be undermined [12,13]. However, it
should be noted that CBT was started from the begin-
ning of the treatment along with fluoxetine, but
significant improvement was observed only when the
treatment was changed over to a combination of
bupropion-SR and CBT. Thus, the therapeutic
response appears more likely to be related to bupro-
pion-SR.
Conclusions
A single case report has associated limitations, especially
when the clinician is not blinded to treatment allocation
and assessments. Also, few of the scales (such as
MGHHPS, NIMH-TSS and NIMH-TIS) are not standar-
dized for the Indian population. However, these case
r e p o r t sd og i v ei n s i g h ti n t ot h en a t u r eo ft h ed i s o r d e r s
discussed, and also help explore new treatment options.
The possibility that TTM may have an addictive compo-
nent needs to be studied further. Bupropion may be
considered as a treatment, especially in case of patients
with TTM who are non-responders to SSRIs. Further
well conducted randomized trials are required to evalu-
ate the effectiveness of bupropion-SR in TTM and other
impulsive-compulsive-addictive spectrum disorders.
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